Medical Devices HTA in Korea

SUKYEONG KIM PHD MPH BPHARM SENIOR RESEARCH FELLOW, INTERNATIONAL COOPERATION ADVISOR EVIDENCE-BASED HEALTHCARE RESEARCH DEPARTMENT

NECA

HTA system overview

		New health technology categories		
low of benefit lecision in NHI		Medical procedure	Medical device	Drug
pproval in use	Safety & efficacy	NECA	MFDS	MFDS
eimbursement sessment	Cost-effectiveness	HIRA	HIRA	HIRA
Pricing	Affordability	HIRA	HIRA	NHIS
↓ Final decision	Final decision		монм	


MOHW (Ministry of Health and Welfare), MFDS (Ministry of Food and Drug Safety), HIRA (Health Insurance Review & Assessment Service), NHIS (National Health Insurance Service), NECA (National Evidence-based Healthcare Collaborating Agency)

Jang J. HTA in Korea - focused on Drug and Reimbursement system, 2013. 10. 4



Pharmaceuticals HTA 2006


• NHI introduced positive list system for the new drugs based on cost-effectiveness



NECA

Medical devices HTA


- Health Technology Assessment for new procedures with medical devices (2006)
 - > Systematic review for safety and effectiveness of procedures (nHTA)





Medical devices HTA improvement

Parallel process of approval, nHTA, and review for NHI coverage introduced in 2014
> Improve patient accessibility to shorten the process



NECA

Medical devices HTA improvement 2

- Conditional use of health technologies (2013)
 - Government supports health interventions for safety and effectiveness evidence generation
 - > Urgent need for rare and severe diseases without alternative treatments
 - > Only in designated hospitals during prescribed time period

Technology	Period	
Autologous Platelet Rich Plasma Application	2014.10-2017.09	
Therapeutic Use of Autologous Petipheral Blood Stem Cell in MI	2014.10-2017.09	
Pancreatic Cancer Inevenible electroporation	2015.09-2018.08	
PET-CT for C-11-Methionine	2016.08~2019.07	
Autologous Platelet Rich Fluid to Vitreous body	2016.11-2019.10	
Smart PreP2 BMAC to Diabetic Critical Limb Ischemia	2018.01-2020.12	
Autologous Adipose Derived Stern Cell Therapy	2018.05-2021.04	

NECA

New policy for medical devices

- Fast tract for In Vitro Diagnostics
 - nHTA exemption, and RWE
 - > Early dialogues from development stage with related agencies
 - > development stage: MFDS
 - > nHTA: NECA
 - ➢ NHI coverage: HIRA

Real One-stop service system

- Unified service team: MFDS, NECA, and HIRA
- Parallel process of regulatory review and nHTA
- R&D support for evidence generation

Differences with Pharmaceutical HTA

- Less mature industry
 - less experience preparing submission
 - Iower quality evidence (historically, and ethically difficult)
- Less obvious patent protection
 - > short life-cycle
 - > frequent functional, minor improvements
- Evidence fundamental
 - > pharmaceutical oriented researchers, experts
 - > data insufficiency (weaker surveillance system)

NECA

Challenges

- New policies are focusing on non-invasive leading edge medical devices
- Guidelines for early dialogues need to be developed
- RWE generation supported by government and industry
- RWE generation needs stronger multidisciplinary approaches and experts of research methodology and data
- International cooperation for improving HTA capacity is important

NECA

Thank You!!